分子和双功能化合物:基于诱导近距离的治疗方式
1Arena BioWorks, Broad Institute, Harvard University, Cambridge, MA, USA.
Cell chemical biology
|June 11, 2024
概括
这项研究检查了诱导近距离的分子和双功能化合物. 这些近距离诱导化合物为了解蛋白质相互作用提供了一个新的框架,并使新的功能结果成为可能.
科学领域:
- 生物化学 生物化学
- 化学生物学 化学生物学
- 药物发现 药物发现 药物发现
背景情况:
- 分子和双功能的化合物是接近诱导剂.
- 了解它们的机制是药物发现的关键.
- 这些化合物可以准原生蛋白或融合蛋白.
研究的目的:
- 为了解分子和双功能化合物提供一个框架.
- 探索它们与蛋白质热点,误解突变和翻译后修饰 (PTM) 的关系.
- 审查这些化合物的历史发展和现代应用.
主要方法:
- 探索现有的文献和数据.
- 开发一个概念框架.
- 分析历史趋势和现代选方法.
主要成果:
- 提出了一个框架,以了解近距离诱导化合物.
- 突出了对分子内和蛋白质域的相关性.
- 现代选产生了合作分子或双功能化合物.
结论:
- 近距离诱导化合物的领域已经显著发展.
- 这些化合物为调节蛋白质功能提供了多功能策略.
- 通过向蛋白质近距离诱导,可以实现新的功能结果.
更多相关视频
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
3.6K
12:30Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
Published on: August 12, 2014
9.8K
相关概念视频
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
